The National Institute for Health and Care Excellence has launched a consultation on draft guidance for ustekinumab (Stelara). The draft guidance proposes to not recommend the use of ustekinumab for treating active psoriatic arthritis in adults when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate. The consultation is available on the NICE website until 17 January 2014.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11132675
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com